Michael A. Sherman - Net Worth and Insider Trading

Michael A. Sherman Net Worth

The estimated net worth of Michael A. Sherman is at least $9 Million dollars as of 2024-05-05. Michael A. Sherman is the President and CEO of Endocyte Inc and owns about 367,837 shares of Endocyte Inc (ECYT) stock worth over $9 Million. Michael A. Sherman is also the CEO of Chimerix Inc and owns about 423,408 shares of Chimerix Inc (CMRX) stock worth over $403,465. Details can be seen in Michael A. Sherman's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Michael A. Sherman has not made any transactions after 2023-05-12 and currently still holds the listed stock(s).

Transaction Summary of Michael A. Sherman

Michael A. Sherman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael A. Sherman owns 5 companies in total, including BioSpecifics Technologies Corp (BSTC) , Chimerix Inc (CMRX) , and Endocyte Inc (ECYT) among others .

Click here to see the complete history of Michael A. Sherman’s form 4 insider trades.

Insider Ownership Summary of Michael A. Sherman

Ticker	Comapny	Transaction Date	Type of Owner
BSTC	BioSpecifics Technologies Corp	2020-05-01	director
CMRX	Chimerix Inc	2023-05-12	director & Chief Executive Officer
ECYT	Endocyte Inc	2018-12-21	director & President and CEO
		2017-06-15	director
		2022-06-01	director

Michael A. Sherman Latest Holdings Summary

Michael A. Sherman currently owns a total of 2 stocks. Among these stocks, Michael A. Sherman owns 367,837 shares of Endocyte Inc (ECYT) as of October 5, 2018, with a value of $9 Million and a weighting of 95.63%. Michael A. Sherman also owns 423,408 shares of Chimerix Inc (CMRX) as of May 12, 2023, with a value of $403,465 and a weighting of 4.37%.

Latest Holdings of Michael A. Sherman

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ECYT	Endocyte Inc	2018-10-05	367,837	23.99	8,824,410
CMRX	Chimerix Inc	2023-05-12	423,408	0.95	403,465

Holding Weightings of Michael A. Sherman

Michael A. Sherman Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael A. Sherman has made a total of 0 transactions in Endocyte Inc (ECYT) over the past 5 years. The most-recent trade in Endocyte Inc is the sale of 28,146 shares on October 5, 2018, which brought Michael A. Sherman around $437,670.

According to the SEC Form 4 filings, Michael A. Sherman has made a total of 3 transactions in Chimerix Inc (CMRX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Chimerix Inc is the acquisition of 87,000 shares on May 12, 2023, which cost Michael A. Sherman around $97,440.

Insider Trading History of Michael A. Sherman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael A. Sherman Trading Performance

GuruFocus tracks the stock performance after each of Michael A. Sherman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael A. Sherman is 22.07%. GuruFocus also compares Michael A. Sherman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael A. Sherman within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael A. Sherman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael A. Sherman

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	10.13
Relative Return to S&P 500(%)	2.9

Michael A. Sherman Ownership Network

Ownership Network List of Michael A. Sherman

No Data

Ownership Network Relation of Michael A. Sherman

Michael A. Sherman Owned Company Details

What does BioSpecifics Technologies Corp do?

Who are the key executives at BioSpecifics Technologies Corp?

Michael A. Sherman is the director of BioSpecifics Technologies Corp. Other key executives at BioSpecifics Technologies Corp include director & 10 percent owner Toby Wegman , director & Chief Executive Officer Joseph Truitt , and Chief Financial Officer Patrick Hutchison .

BioSpecifics Technologies Corp (BSTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioSpecifics Technologies Corp (BSTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioSpecifics Technologies Corp (BSTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioSpecifics Technologies Corp (BSTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioSpecifics Technologies Corp Insider Transactions

No Available Data

What does Chimerix Inc do?

Who are the key executives at Chimerix Inc?

Michael A. Sherman is the director & Chief Executive Officer of Chimerix Inc. Other key executives at Chimerix Inc include Principal Accounting Officer David Jakeman , Chief Business Officer Michael T. Andriole , and 10 percent owner Cantex Pharmaceuticals, Inc. .

Chimerix Inc (CMRX) Insider Trades Summary

Over the past 18 months, Michael A. Sherman made 1 insider transaction in Chimerix Inc (CMRX) with a net purchase of 87,000. Other recent insider transactions involving Chimerix Inc (CMRX) include a net purchase of 60,000 shares made by Fred A Middleton , a net sale of 9,500 shares made by David Jakeman , and a net purchase of 18,000 shares made by Martha J Demski .

In summary, during the past 3 months, insiders sold 6,344 shares of Chimerix Inc (CMRX) in total and bought 0 shares, with a net sale of 6,344 shares. During the past 18 months, 13,184 shares of Chimerix Inc (CMRX) were sold and 173,750 shares were bought by its insiders, resulting in a net purchase of 160,566 shares.

Chimerix Inc (CMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chimerix Inc Insider Transactions

No Available Data

What does Endocyte Inc do?

Who are the key executives at Endocyte Inc?

Michael A. Sherman is the director & President and CEO of Endocyte Inc. Other key executives at Endocyte Inc include VP Finance & Chief Acctg Off Beth Taylor , General Counsel David R. Mcavoy , and Chief Medical Officer Alison A. Armour .

Endocyte Inc (ECYT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Endocyte Inc (ECYT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Endocyte Inc (ECYT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Endocyte Inc (ECYT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Endocyte Inc Insider Transactions

No Available Data

What does Mead Johnson Nutrition Co do?

Who are the key executives at Mead Johnson Nutrition Co?

Michael A. Sherman is the director of Mead Johnson Nutrition Co. Other key executives at Mead Johnson Nutrition Co include SVP and Controller James E. Shiah , SVP & Gen. Counsel & Secretary Patrick M Sheller , and EVP and CFO Peter G Leemputte .

Mead Johnson Nutrition Co (MJN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mead Johnson Nutrition Co (MJN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mead Johnson Nutrition Co (MJN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mead Johnson Nutrition Co (MJN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mead Johnson Nutrition Co Insider Transactions

No Available Data

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Michael A. Sherman is the director of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Technology Officer Chulani Karunatilake , and Chief Operating Officer Reid Leonard .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

Over the past 18 months, Michael A. Sherman made no insider transaction in Werewolf Therapeutics Inc (HOWL). Other recent insider transactions involving Werewolf Therapeutics Inc (HOWL) include a net purchase of 1,853,000 shares made by Ra Capital Healthcare Fund Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Werewolf Therapeutics Inc (HOWL) were sold and 1,853,000 shares were bought by its insiders, resulting in a net purchase of 1,853,000 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

Michael A. Sherman Mailing Address

Above is the net worth, insider trading, and ownership report for Michael A. Sherman. You might contact Michael A. Sherman via mailing address: 3000 Kent Ave Ste A1-100, West Lafayette In 47906.

Discussions on Michael A. Sherman

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.